EDIT vs. BEAM

Last updated Apr 1, 2026

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and Beam Therapeutics Inc. (BEAM).

Performance

EDIT vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

EDIT vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
EDIT Editas Medicine, Inc.	20.49%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	149.95%
BEAM Beam Therapeutics Inc.	-14.03%	11.77%	-8.89%	-30.40%	-50.92%	-2.39%	335.41%

Fundamentals

Market Cap EDIT : $219.20M BEAM : $2.50B
EPS EDIT : -$1.82 BEAM : -$0.78
PS Ratio EDIT : 5.35 BEAM : 95.90
PB Ratio EDIT : 8.03 BEAM : 2.02
Total Revenue (TTM) EDIT : $40.52M BEAM : $25.63M
Gross Profit (TTM) EDIT : $39.72M BEAM : -$284.71M
EBITDA (TTM) EDIT : $0.00 BEAM : -$352.98M

Returns By Period

In the year-to-date period, EDIT achieves a 20.49% return, which is significantly higher than BEAM's -14.03% return.

EDIT

• 1D: 10.76%
• 1M: 12.27%
• YTD: 20.49%
• 6M: -28.82%
• 1Y: 112.93%
• 3Y*: -30.16%
• 5Y*: -43.48%
• 10Y*: -23.69%

BEAM

• 1D: 8.81%
• 1M: -16.27%
• YTD: -14.03%
• 6M: -1.81%
• 1Y: 22.02%
• 3Y*: -8.02%
• 5Y*: -21.46%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EDIT vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 75
EDIT Sharpe Ratio Rank: 78
EDIT Sortino Ratio Rank: 82
EDIT Omega Ratio Rank: 75
EDIT Calmar Ratio Rank: 73
EDIT Martin Ratio Rank: 68

BEAM

BEAM Risk / Return Rank: 52
BEAM Sharpe Ratio Rank: 53
BEAM Sortino Ratio Rank: 57
BEAM Omega Ratio Rank: 54
BEAM Calmar Ratio Rank: 47
BEAM Martin Ratio Rank: 47

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EDIT	BEAM	Difference
Sharpe ratio Return per unit of total volatility	1.16	0.29	+0.87
Sortino ratio Return per unit of downside risk	2.16	1.03	+1.12
Omega ratio Gain probability vs. loss probability	1.24	1.12	+0.12
Calmar ratio Return relative to maximum drawdown	1.63	0.19	+1.44
Martin ratio Return relative to average drawdown	3.10	0.42	+2.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EDIT vs. BEAM - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 1.16, which is higher than the BEAM Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of EDIT and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EDIT	BEAM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.16	0.29	+0.87
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.47	-0.29	-0.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.21	0.05	-0.26

Correlation

The correlation between EDIT and BEAM is 0.67, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

EDIT vs. BEAM - Dividend Comparison

Neither EDIT nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. BEAM - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for EDIT and BEAM.

Drawdown Indicators

	EDIT	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	-89.12%	-9.80%
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	-38.15%	-21.73%
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	-89.12%	-9.54%
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	—	—
Current Drawdown Current decline from peak	-97.27%	-82.16%	-15.11%
Average Drawdown Average peak-to-trough decline	-61.98%	-59.29%	-2.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.49%	17.33%	+14.16%

Volatility

EDIT vs. BEAM - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 31.71% compared to Beam Therapeutics Inc. (BEAM) at 17.93%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EDIT	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	31.71%	17.93%	+13.78%
Volatility (6M) Calculated over the trailing 6-month period	60.26%	53.97%	+6.29%
Volatility (1Y) Calculated over the trailing 1-year period	98.42%	78.23%	+20.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.19%	75.45%	+17.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.41%	80.57%	+2.84%

Financials